A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma - A Hoosier Oncology Group study

Brian R. Murphy, Susan M. Rynard, Lawrence Einhorn, Patrick Loehrer

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In vitro studies have documented the synergistic activity of interferon (IFN) and fluorouracil (5-FU) in human cancer cell lines, and recent clinical trials have demonstrated the efficacy of this combination in metastatic colon cancer. The current study was undertaken to evaluate the combination of IFN alpha-2a plus 5-FU in previously untreated patients with metastatic renal cell carcinoma. From May 1990 through August 1990, 14 patients with metastatic renal cell carcinoma were treated with 5-FU 750 mg/m2 day continuous infusion IV days 1-5, followed by weekly IV infusions of 5-FU 750 mg/m2 beginning on day 12. Patients concurrently received IFN alpha-2a 9×106 IU subcutaneously 3 times per week beginning on day 1. The median age of patients treated was 57 (range 38-80) with a median Karnofsky performance status of 90 (range 60-100). Sites of metastases included lung only in 6 patients, liver only in 1 patient, 1 patient had bilateral disease at presentation, and the remaining patients had multiple sites of metastases. The median duration of therapy was 2 months. The predominant toxicities seen were stomatitis, nausea, flu-like symptoms and neurotoxicity. The only grade IV toxicity observed was severe vomiting in 1 patient, though 5 patients discontinued therapy within 2 months because of poor subjective response. With a minimum follow-up of 13 months no objective responses were seen. Thirteen of the 14 patients have had progressive disease and 11 have died. The median time to progression was 2 months (range 0.5-6 months) and the median survival was 5 months (range 2-14.5+months). We conclude that at this dose and schedule, IFN alpha-2a plus 5-FU is ineffective in the treatment of advanced renal cell carcinoma.

Original languageEnglish
Pages (from-to)225-230
Number of pages6
JournalInvestigational New Drugs
Volume10
Issue number3
DOIs
StatePublished - Aug 1992

Fingerprint

Renal Cell Carcinoma
Fluorouracil
interferon alfa-2a
Neoplasm Metastasis
Karnofsky Performance Status
Stomatitis
Colonic Neoplasms
Nausea
Interferons
Vomiting
Appointments and Schedules
Therapeutics
Clinical Trials
Cell Line
Lung
Survival
Liver

Keywords

  • fluorouracil
  • interferon
  • renal cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma - A Hoosier Oncology Group study. / Murphy, Brian R.; Rynard, Susan M.; Einhorn, Lawrence; Loehrer, Patrick.

In: Investigational New Drugs, Vol. 10, No. 3, 08.1992, p. 225-230.

Research output: Contribution to journalArticle

@article{271d87f930f8435fb7e3e96a1fd6be76,
title = "A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma - A Hoosier Oncology Group study",
abstract = "In vitro studies have documented the synergistic activity of interferon (IFN) and fluorouracil (5-FU) in human cancer cell lines, and recent clinical trials have demonstrated the efficacy of this combination in metastatic colon cancer. The current study was undertaken to evaluate the combination of IFN alpha-2a plus 5-FU in previously untreated patients with metastatic renal cell carcinoma. From May 1990 through August 1990, 14 patients with metastatic renal cell carcinoma were treated with 5-FU 750 mg/m2 day continuous infusion IV days 1-5, followed by weekly IV infusions of 5-FU 750 mg/m2 beginning on day 12. Patients concurrently received IFN alpha-2a 9×106 IU subcutaneously 3 times per week beginning on day 1. The median age of patients treated was 57 (range 38-80) with a median Karnofsky performance status of 90 (range 60-100). Sites of metastases included lung only in 6 patients, liver only in 1 patient, 1 patient had bilateral disease at presentation, and the remaining patients had multiple sites of metastases. The median duration of therapy was 2 months. The predominant toxicities seen were stomatitis, nausea, flu-like symptoms and neurotoxicity. The only grade IV toxicity observed was severe vomiting in 1 patient, though 5 patients discontinued therapy within 2 months because of poor subjective response. With a minimum follow-up of 13 months no objective responses were seen. Thirteen of the 14 patients have had progressive disease and 11 have died. The median time to progression was 2 months (range 0.5-6 months) and the median survival was 5 months (range 2-14.5+months). We conclude that at this dose and schedule, IFN alpha-2a plus 5-FU is ineffective in the treatment of advanced renal cell carcinoma.",
keywords = "fluorouracil, interferon, renal cell carcinoma",
author = "Murphy, {Brian R.} and Rynard, {Susan M.} and Lawrence Einhorn and Patrick Loehrer",
year = "1992",
month = "8",
doi = "10.1007/BF00877251",
language = "English",
volume = "10",
pages = "225--230",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma - A Hoosier Oncology Group study

AU - Murphy, Brian R.

AU - Rynard, Susan M.

AU - Einhorn, Lawrence

AU - Loehrer, Patrick

PY - 1992/8

Y1 - 1992/8

N2 - In vitro studies have documented the synergistic activity of interferon (IFN) and fluorouracil (5-FU) in human cancer cell lines, and recent clinical trials have demonstrated the efficacy of this combination in metastatic colon cancer. The current study was undertaken to evaluate the combination of IFN alpha-2a plus 5-FU in previously untreated patients with metastatic renal cell carcinoma. From May 1990 through August 1990, 14 patients with metastatic renal cell carcinoma were treated with 5-FU 750 mg/m2 day continuous infusion IV days 1-5, followed by weekly IV infusions of 5-FU 750 mg/m2 beginning on day 12. Patients concurrently received IFN alpha-2a 9×106 IU subcutaneously 3 times per week beginning on day 1. The median age of patients treated was 57 (range 38-80) with a median Karnofsky performance status of 90 (range 60-100). Sites of metastases included lung only in 6 patients, liver only in 1 patient, 1 patient had bilateral disease at presentation, and the remaining patients had multiple sites of metastases. The median duration of therapy was 2 months. The predominant toxicities seen were stomatitis, nausea, flu-like symptoms and neurotoxicity. The only grade IV toxicity observed was severe vomiting in 1 patient, though 5 patients discontinued therapy within 2 months because of poor subjective response. With a minimum follow-up of 13 months no objective responses were seen. Thirteen of the 14 patients have had progressive disease and 11 have died. The median time to progression was 2 months (range 0.5-6 months) and the median survival was 5 months (range 2-14.5+months). We conclude that at this dose and schedule, IFN alpha-2a plus 5-FU is ineffective in the treatment of advanced renal cell carcinoma.

AB - In vitro studies have documented the synergistic activity of interferon (IFN) and fluorouracil (5-FU) in human cancer cell lines, and recent clinical trials have demonstrated the efficacy of this combination in metastatic colon cancer. The current study was undertaken to evaluate the combination of IFN alpha-2a plus 5-FU in previously untreated patients with metastatic renal cell carcinoma. From May 1990 through August 1990, 14 patients with metastatic renal cell carcinoma were treated with 5-FU 750 mg/m2 day continuous infusion IV days 1-5, followed by weekly IV infusions of 5-FU 750 mg/m2 beginning on day 12. Patients concurrently received IFN alpha-2a 9×106 IU subcutaneously 3 times per week beginning on day 1. The median age of patients treated was 57 (range 38-80) with a median Karnofsky performance status of 90 (range 60-100). Sites of metastases included lung only in 6 patients, liver only in 1 patient, 1 patient had bilateral disease at presentation, and the remaining patients had multiple sites of metastases. The median duration of therapy was 2 months. The predominant toxicities seen were stomatitis, nausea, flu-like symptoms and neurotoxicity. The only grade IV toxicity observed was severe vomiting in 1 patient, though 5 patients discontinued therapy within 2 months because of poor subjective response. With a minimum follow-up of 13 months no objective responses were seen. Thirteen of the 14 patients have had progressive disease and 11 have died. The median time to progression was 2 months (range 0.5-6 months) and the median survival was 5 months (range 2-14.5+months). We conclude that at this dose and schedule, IFN alpha-2a plus 5-FU is ineffective in the treatment of advanced renal cell carcinoma.

KW - fluorouracil

KW - interferon

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0026495621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026495621&partnerID=8YFLogxK

U2 - 10.1007/BF00877251

DO - 10.1007/BF00877251

M3 - Article

C2 - 1428732

AN - SCOPUS:0026495621

VL - 10

SP - 225

EP - 230

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -